东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002675 东诚药业

已收盘 07-11 15:00:00

{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":14.36,"timestamp":1752217416000,"preClose":14.35,"halted":0,"volume":8431800,"delay":0,"changeRate":0.0007,"floatShares":743000000,"shares":825000000,"eps":0.175,"marketStatus":"已收盘","change":0.01,"latestTime":"07-11 15:00:00","open":14.35,"high":14.58,"low":14.3,"amount":121000000,"amplitude":0.0195,"askPrice":14.37,"askSize":828,"bidPrice":14.36,"bidSize":153,"shortable":0,"etf":0,"ttmEps":0.175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752456600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.35,"symbolType":"stock","openAndCloseTimeList":[[1752197400000,1752204600000],[1752210000000,1752217200000]],"highLimit":15.79,"lowLimit":12.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.63,"roa":"--","peRate":82.057143,"roe":"0.55%","epsLYR":0.2229,"committee":0.076964,"marketValue":11841000000,"turnoverRate":0.0113,"status":0,"floatMarketCap":10675000000},"requestUrl":"/m/hq/s/002675","defaultTab":"news","newsList":[{"id":"2550527799","title":"东诚药业获得发明专利授权：“一种高产果糖软骨素的大肠杆菌及其生产方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2550527799","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550527799?lang=zh_cn&edition=full","pubTime":"2025-07-09 02:32","pubTimestamp":1751999535,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示东诚药业新获得一项发明专利授权，专利名为“一种高产果糖软骨素的大肠杆菌及其生产方法”，专利申请号为CN202510314998.0，授权日为2025年7月8日。今年以来东诚药业新获得专利授权2个，较去年同期增加了100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900001427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2543506628","title":"东诚药业(002675.SZ)：氟[18F]思睿肽注射液III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2543506628","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543506628?lang=zh_cn&edition=full","pubTime":"2025-06-13 16:32","pubTimestamp":1749803543,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业 发布公告，近日，公司控股子公司烟台蓝纳成生物技术股份有限公司组织开展的氟[18F]思睿肽注射液III期临床试验，目前已完成全部488例受试者入组。氟[18F]思睿肽注射液是一种靶向PSMA的放射性体内诊断药物，适用于下述前列腺癌患者前列腺特异性膜抗原阳性病灶的正电子发射断层扫描成像：拟接受初始根治性治疗，怀疑存在转移灶的前列腺癌患者;血清前列腺特异性抗原水平升高，怀疑生化复发的前列腺癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1304950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1576","BK0239","BK1583","III","BK1141","BK4134","002675"],"gpt_icon":0},{"id":"2542753801","title":"东诚药业：基于国内放药法规的完善与审评要求的提升，APN-1607产品计划上市前在原基础上进一步开展杂质研究等工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2542753801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542753801?lang=zh_cn&edition=full","pubTime":"2025-06-09 16:45","pubTimestamp":1749458719,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：18F-APN-1607注射液为阿尔茨海默症的tau蛋白过度磷酸化导致神经元纤维缠结成像的正电子显像剂，已于2023年12月底提前完成临床III期受试者全部入组，后续将进行临床总结，上市申请等工作。东诚药业回复：您好，基于国内放药法规的完善与审评要求的提升，APN-1607 产品计划上市前在原基础上进一步开展杂质研究等工作，公司将积极推动研发进度，争取尽早上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900020753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2542809021","title":"东诚药业：公司为南京中硼联康的参股股东，持股比例为11.8512%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542809021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542809021?lang=zh_cn&edition=full","pubTime":"2025-06-09 16:36","pubTimestamp":1749458203,"startTime":"0","endTime":"0","summary":"您好，公司为南京中硼联康的参股股东，持股比例为11.8512%，中硼联康是国内较早开拓加速器硼中子治疗产业的领先企业，致力于先进BNCT治疗系统及配套软件、药物的自主开发，基于国际领先的技术水准，卓越的质量管控能力和协同高效的现代供应链体系，持续探索创新，推动新一代肿瘤治疗技术纵深发展，让癌症治疗更高效、精准和便捷。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900020465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2538458816","title":"东诚药业(002675.SZ)：氟[18F]化钠注射液通过药品上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2538458816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538458816?lang=zh_cn&edition=full","pubTime":"2025-05-27 16:10","pubTimestamp":1748333415,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业 发布公告，近日，公司全资子公司南京江原安迪科正电子研究发展有限公司收到国家药品监督管理局核准签发的氟[18F]化钠注射液《药品注册证书》，氟[18F]化钠注射液通过药品上市许可申请，可生产销售。本次安迪科获得国家药监局核准签发的氟[18F]化钠注射液《药品注册证书》，将进一步丰富公司产品线，有利于提升公司产品的市场竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2537667891","title":"每周股票复盘：东诚药业（002675）2024年度权益分派实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2537667891","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537667891?lang=zh_cn&edition=full","pubTime":"2025-05-24 10:07","pubTimestamp":1748052433,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘，东诚药业报收于14.55元，较上周的14.5元上涨0.34%。本周，东诚药业5月21日盘中最高价报14.88元。东诚药业当前最新总市值119.98亿元，在化学制药板块市值排名37/150，在两市A股市值排名1284/5148。本周关注点公司公告汇总：东诚药业2024年度权益分派方案为每10股派发现金股利人民币0.30元，共计派发24,737,871.15元。分配方案披露后至实施期间公司股本总额没有发生变化。A股股东现金红利将于2025年5月27日通过股东托管证券公司直接划入其资金账户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400010822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2533687311","title":"东诚药业(002675.SZ)：注射用氢化可的松琥珀酸钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2533687311","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533687311?lang=zh_cn&edition=full","pubTime":"2025-05-06 19:52","pubTimestamp":1746532327,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业 发布公告，近日，公司全资子公司烟台东诚北方制药有限公司收到国家药品监督管理局核准签发的关于注射用氢化可的松琥珀酸钠的《药品补充申请批准通知书》，东诚北方生产的注射用氢化可的松琥珀酸钠通过仿制药质量和疗效一致性评价。氢化可的松琥珀酸钠是氢化可的松的盐类化合物，具有抗炎、抗过敏和抑制免疫等多种药理作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2532013556","title":"东诚药业（002675）2025年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2532013556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532013556?lang=zh_cn&edition=full","pubTime":"2025-05-01 06:56","pubTimestamp":1746053772,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期东诚药业发布2025年一季报。根据财报显示，东诚药业增收不增利。截至本报告期末，公司营业总收入6.87亿元，同比上升6.13%，归母净利润2473.15万元，同比下降61.55%。持有东诚药业最多的基金为银河医药混合A，目前规模为4.93亿元，最新净值0.4994，较上一交易日上涨0.5%，近一年上涨0.57%。2025 年在搭建基础工作的过程中，也会有销售收入的增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100005584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2531086413","title":"东诚药业(002675)3月31日股东户数2.16万户，较上期减少12.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531086413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531086413?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:51","pubTimestamp":1746006715,"startTime":"0","endTime":"0","summary":"证券之星消息，近日东诚药业披露，截至2025年3月31日公司股东户数为2.16万户，较1月31日减少3085.0户，减幅为12.51%。在化学制药行业个股中，东诚药业股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.2万户。从股价来看，2025年1月31日至2025年3月31日，东诚药业区间涨幅为3.86%，在此期间股东户数减少3085.0户，减幅为12.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000036680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2531659732","title":"东诚药业最新公告：拟3600万元收购控股子公司蓝纳成少数股东股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2531659732","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531659732?lang=zh_cn&edition=full","pubTime":"2025-04-29 21:19","pubTimestamp":1745932773,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司拟以约3600万元人民币收购控股子公司烟台蓝纳成生物技术股份有限公司少数股东深圳景林景盈股权投资基金合伙企业所持1.65%股份。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900042495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2527463328","title":"【量价齐升榜前十：康鹏科技连续5天放量上涨，累计涨幅27.18%】截至4月15日收盘，康鹏科技量价齐升，连续5天放量上涨，累计涨幅27.18%。其余量价齐升的上涨个股还包括：红宝丽（放量上涨4天）、浙江永强（放量上涨4天）、深康佳A（放量上涨3天）、深圳华强（放量上涨3天）、川润股份（放量上涨3天）、信立泰（放量上涨3天）、大金重工（放量上涨3天）、跨境通（放量上涨3天）、东诚药业（放量上涨3天）。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527463328","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527463328?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:42","pubTimestamp":1744706548,"startTime":"0","endTime":"0","summary":"截至4月15日收盘，康鹏科技量价齐升，连续5天放量上涨，累计涨幅27.18%。其余量价齐升的上涨个股还包括：红宝丽（放量上涨4天）、浙江永强（放量上涨4天）、深康佳A（放量上涨3天）、深圳华强（放量上涨3天）、川润股份（放量上涨3天）、信立泰（放量上涨3天）、大金重工（放量上涨3天）、跨境通（放量上涨3天）、东诚药业（放量上涨3天）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/15164249547482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0012","002640","BK0077","002487","BK0172","BK0174","BK0137","002675","BK0070","002165","BK0209","002489","BK0200","BK0107","BK0214","BK0250","BK0120","BK0183","BK0196","BK0256","002272","BK0229","002294","BK0118","BK0188","000062","000016","BK0050","BK0239","BK0126","BK0138","BK0260","BK0185","BK0187","BK0259","688602","BK0028","BK0010"],"gpt_icon":0},{"id":"2527946447","title":"【创新药概念反复活跃，一品红涨超10%续创历史新高】一品红涨超10%，股价续创历史新高，东诚药业涨停，悦康药业、科兴制药、智翔金泰、前沿生物、热景生物、百济神州等涨幅靠前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527946447","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527946447?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:55","pubTimestamp":1744595733,"startTime":"0","endTime":"0","summary":"一品红涨超10%，股价续创历史新高，东诚药业涨停，悦康药业、科兴制药、智翔金泰、前沿生物、热景生物、百济神州等涨幅靠前。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/14095549514272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06978","BK1588","LU1969619763.USD","BK4139","LU0588546209.SGD","688136","BK1574","688068","688235","06160","BK0239","ONC","BK1161","688221","BK1500","688658","002675","LU0307460666.USD","688443","LU2328871848.SGD","159992","BK1583","300723"],"gpt_icon":0},{"id":"2517487145","title":"东诚药业：公司在追求经济效益的同时注重环境保护和节能降耗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517487145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517487145?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:50","pubTimestamp":1741351818,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)03月07日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，我是一名公民，想请问贵公司在生产活动中，是否采取过一些相关措施来减少空气污染呢？希望贵公司能与我们一起提升空气质量，建设美好家园。东诚药业回复：您好，公司在追求经济效益的同时注重环境保护和节能降耗，把建设资源节约型和环境友好型企业作为可持续发展战略的重要内容。感谢您的关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700042357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2517145921","title":"原料药拖累业绩 东诚药业转向核药","url":"https://stock-news.laohu8.com/highlight/detail?id=2517145921","media":"媒体滚动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517145921?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:46","pubTimestamp":1741283160,"startTime":"0","endTime":"0","summary":"业绩下滑背后，东诚药业传统原料药业务受降价影响销售收入出现明显下滑。从公司业务构成看，原料药业务为东诚药业第一大营收来源，不过占比正逐年降低，2024年已掉到50%以下。随着原料药营收占比下降，东诚药业押注多年的核药业务占比提升，也是公司目前正大力发展的方向。3月5日，东诚药业召开2024年业绩说明会，针对投资者重点关注的公司业绩下滑、新产品研发等问题一一进行回应。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-03-07/doc-inentxuv7506518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2517199705","title":"东诚药业：3月5日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2517199705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517199705?lang=zh_cn&edition=full","pubTime":"2025-03-05 19:01","pubTimestamp":1741172489,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年3月5日东诚药业发布公告称公司于2025年3月5日召开业绩说明会。主要原因是原料药中肝素钠产品的销售价格大幅下降，尽管销量有所增长，但价格的下降导致整体收入下滑；2024 年公司归母净利润为 1.8 亿元，同比下降 12%，主要受到原料药销售价格下滑、研发投入大幅增加和融资带来的财务费用增加三方面影响。东诚药业主营业务：主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500033985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2514835508","title":"东诚药业（002675）2024年年报简析：净利润减12.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514835508?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:02","pubTimestamp":1740693733,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期东诚药业发布2024年年报。根据财报显示，东诚药业净利润减12.35%。截至本报告期末，公司营业总收入28.69亿元，同比下降12.42%，归母净利润1.84亿元，同比下降12.35%。按单季度数据看，第四季度营业总收入7.07亿元，同比上升2.35%，第四季度归母净利润1695.76万元，同比上升122.29%。持有东诚药业最多的基金为银河医药混合A，目前规模为4.81亿元，最新净值0.5116，较上一交易日上涨0.47%，近一年上涨4.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022800005242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675"],"gpt_icon":0},{"id":"2514878489","title":"东诚药业(002675)1月31日股东户数2.47万户，较上期减少2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514878489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514878489?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:11","pubTimestamp":1740647497,"startTime":"0","endTime":"0","summary":"证券之星消息，近日东诚药业披露，截至2025年1月31日公司股东户数为2.47万户，较12月31日减少528.0户，减幅为2.1%。在化学制药行业个股中，东诚药业股东户数低于行业平均水平，截至1月31日，化学制药行业平均股东户数为3.09万户。从股价来看，2024年12月31日至2025年1月31日，东诚药业区间涨幅为3.76%，在此期间股东户数减少528.0户，减幅为2.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700029512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2514828676","title":"东诚药业：拟使用不超4亿元闲置自有资金购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2514828676","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514828676?lang=zh_cn&edition=full","pubTime":"2025-02-27 15:10","pubTimestamp":1740640202,"startTime":"0","endTime":"0","summary":"中国财富通2月27日 - 东诚药业（002675）公告称，2月26日，公司第六届董事会第九次会议和第六届监事会第七次会议审议通过了《关于使用闲置自有资金购买理财产品的议案》，同意公司及子公司使用自有资金不超过人民币4亿元购买理财产品。在上述额度内，资金可以滚动使用。该事项尚需提请公司股东大会审议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=G0o97otA9fM%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2514863503","title":"图解东诚药业年报：第四季度单季净利润同比增122.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514863503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514863503?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:11","pubTimestamp":1740589886,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业2024年年报显示，公司主营收入28.69亿元，同比下降12.42%；归母净利润1.84亿元，同比下降12.35%；扣非净利润7927.4万元，同比下降62.69%；其中2024年第四季度，公司单季度主营收入7.07亿元，同比上升2.35%；单季度归母净利润1695.76万元，同比上升122.29%；单季度扣非净利润-7104.24万元，同比下降85.9%；负债率37.79%，投资收益-1398.5万元，财务费用7723.37万元，毛利率47.14%。筹资活动现金流出小计变动幅度为42.39%,原因:本期支付的租金同比增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700000375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675"],"gpt_icon":0},{"id":"2514836476","title":"东诚药业最新公告：2024年净利同比下降12.35% 拟10派0.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514836476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514836476?lang=zh_cn&edition=full","pubTime":"2025-02-26 19:49","pubTimestamp":1740570563,"startTime":"0","endTime":"0","summary":"东诚药业发布2024年度报告，2024年实现营业收入28.69亿元，同比下降12.42%；净利润1.84亿元，同比下降12.35%；基本每股收益0.22元。公司拟每10股派发现金红利0.3元（含税）。报告期内，公司原料药业务板块销售收入12.55亿元，同比下降25.17%，其中重点产品肝素类原料药产品实现营业收入8.44亿元，同比下降36.32%。肝素产品销售收入下降，主要原因为肝素钠销售价格下降。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022600036763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752432670518,"stockEarnings":[{"period":"1week","weight":-0.0362},{"period":"1month","weight":-0.0602},{"period":"3month","weight":0.1103},{"period":"6month","weight":0.1882},{"period":"1year","weight":0.1784},{"period":"ytd","weight":0.1776}],"compareEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.0317},{"period":"3month","weight":0.084},{"period":"6month","weight":0.1078},{"period":"1year","weight":0.1817},{"period":"ytd","weight":0.0473}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21576人(较上一季度减少12.51%)","perCapita":"34454股","listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":"　　烟台东诚药业集团股份有限公司的主营业务是生化原料药、中西药制剂、放射性核素药物的研发、生产、销售。公司的主要产品是肝素钠原料药、硫酸软骨素、那屈肝素钙注射液、注射用氢化可的松琥珀酸钠、达肝素钠注射液、依诺肝素钠注射液、注射用绒促性素、注射用尿促性素。公司连续七年荣登“中国化药企业TOP100排行榜”，连续四年荣登“中国医药工业百强榜”，连续三年荣获“山东民营企业创新100强”，本年度公司首次荣获“2024中国化药研发实力100强”。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}